Meeting
2023 ASCO Annual Meeting
Impact of race on BluePrint genomic subtyping in HER2+ breast cancer.
Authors
Sonya A. Reid
Vanderbilt-Ingram Cancer Center, Nashville, TN
Sonya A. Reid , Tuya Pal , Xiao-Ou Shu , Lindsay Venton , Jennifer G. Whisenant , Kent Hoskins , Eduardo Dias , Rakhshanda Layeequr Rahman , Jennifer Wei , Sahra Uygun , Ciera S Singleton , Andrea Menicucci , Patricia Dauer , William M. Audeh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 564)
DOI
10.1200/JCO.2023.41.16_suppl.564
Abstract #
564
Poster Bd #
394
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.
First Author: Christian F. Singer
Poster
2022 ASCO Annual Meeting
DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade.
First Author: Veronique Debien
Poster
2019 ASCO Annual Meeting
Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.
First Author: Ning Liao
Poster
2019 ASCO Annual Meeting
Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.
First Author: Luca Gianni